Table 2 Univariate analysis.
Variables | Positive group (n = 92) | Negative group (n = 92) | X2/U | P | |
|---|---|---|---|---|---|
CNLC (n, %) | Ia, 1b | 40, 43.5% | 47, 51.1% | 4.558 | 0.102 |
IIa, IIb | 7, 7.6% | 13, 14.1% | |||
IIIa, IIIb | 45, 48.9% | 32, 34.8% | |||
Antitumor drugs(n, %) | Yes | 34, 37% | 17, 18.5% | 7.840 | 0.005* |
No | 58, 63% | 75, 81.5% | |||
Antipyretic analgesics (n, %) | Yes | 34, 37% | 21, 22.8% | 4.383 | 0.036* |
No | 58, 63% | 71, 77.2% | |||
Cephalosporins (n, %) | Yes | 31, 33.7% | 17, 18.5% | 5.525 | 0.019* |
No | 61, 66.3% | 75, 81.5% | |||
Diuretics (n, %) | Yes | 27, 29.3% | 24, 26.1% | 0.244 | 0.621 |
No | 65, 70.7% | 68, 73.9% | |||
HBV-DNA(n, %) | > 1000 COPY/ML | 24, 26.1% | 23, 25% | 0.029 | 0.866 |
< = 1000 COPY/ML | 68, 73.9% | 69, 75% | |||
PIVKA-II (mAU/mL) | Median | 227 | 162 | 4168 | 0.859 |
AFP (ng/mL) | Median | 22.10 | 93.63 | 3784 | 0.215 |
CA199 (U/mL) | Median | 24.5 | 20.41 | 3916.5 | 0.382 |
CEA (ng/mL) | Median | 2.94 | 2.65 | 3571 | 0.067 |
